In vitro study demonstrated that KRAS G12C mutated CRC cell lines have high basal RTK activity, and inhibiting KRAS G12C induces increased phospho-ERK rebound (Figures 1A and 1B). The gene discussed is KRAS; the disease is colorectal carcinoma.